Impaired interferon signaling is a common immune defect in human cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 22, 2009, Pages 9010-9015

  Critchley Thorne, Rebecca J ^a   Simons, Diana L ^a   Yan, Ning ^a,b   Miyahira, Andrea K ^a   Dirbas, Frederick M ^a   Johnson, Denise L ^a   Swetter, Susan M ^c,d   Carlson, Robert W ^a   Fisher, George A ^a   Koong, Albert ^a   Holmes, Susan ^b   Lee, Peter P ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MALE; MELANOMA; NATURAL KILLER CELL; OUTCOME ASSESSMENT; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BREAST NEOPLASMS; COHORT STUDIES; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNITY; IMMUNOLOGIC MEMORY; INTERFERON-ALPHA; INTERFERON-GAMMA; MALE; MELANOMA; MIDDLE AGED; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

ANIMALIA;

EID: 67049158197     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0901329106     Document Type: Article

References (36)

1. Staveley-O'Carroll K, et al. (1998) Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA 95:1178-1183. (Pubitemid 28124932)
2. Lee PP, et al. (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5:677-685. (Pubitemid 29289432)
3. Anichini A, et al. (1999) An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 190:651-667. (Pubitemid 29429007)
4. Lee KH, et al. (1999) Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 163:6292-6300.
5. Weber J, et al. (2003) Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 97:186-200. (Pubitemid 36033878)
6. Saito T, Dworacki G, Gooding W, Lotze MT, Whiteside TL (2000) Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res 6:1351-1364. (Pubitemid 30226220)
7. Zippelius A, et al. (2004) Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 64:2865-2873. (Pubitemid 38500627)
8. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF (2005) Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 174:4465-4469. (Pubitemid 40504523)
9. Reiter Z (1993) Interferon-a major regulator of natural killer cell-mediated cytotoxicity. J Interferon Res 13:247-257. (Pubitemid 23318486)
10. Critchley-Thorne RJ, et al. (2007) Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 4:e176. (Pubitemid 46842580)
11. Darnell JE, Jr, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421. (Pubitemid 24217131)
12. Bernabei P, et al. (2003) IGF-1 down-regulates IFN-gamma R2 chain surface expression and desensitizes IFN-gamma/STAT-1 signaling in human T lymphocytes. Blood 102:2933-2939. (Pubitemid 37248867)
13. Haring JS, Corbin GA, Harty JT (2005) Dynamic regulation of IFN-gamma signaling in antigen-specific CD8+ T cells responding to infection. J Immunol 174:6791-6802. (Pubitemid 40705642)
14. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK (2002) Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med 196:999-1005.
15. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL (2004) Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin. Cancer Res 10:3755-3762. (Pubitemid 38697609)
16. Dondi E, Roue G, Yuste VJ, Susin SA, Pellegrini S (2004) A dual role of IFN-alpha in the balance between proliferation and death of human CD4+ T lymphocytes during primary response. J Immunol 173:3740-3747. (Pubitemid 39280735)
17. Havenar-Daughton C, Kolumam GA, Murali-Krishna K (2006) Cutting edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J Immunol 176:3315-3319. (Pubitemid 43363977)
18. Le Bon A, et al. (2006) Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 176:2074-2078. (Pubitemid 43201653)
19. Jewett A, Bonavida B (1995) Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells. J Clin Immunol 15:35-44.
20. Lai P, et al. (1996) Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res 2:161-173. (Pubitemid 26042190)
21. Dworacki G, et al. (2001) Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 7:947s-957s. (Pubitemid 33600950)
22. Chaussabel D, et al. (2008) A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29:150-164. (Pubitemid 351952461)
23. Guillot B, et al. (2005) The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment. Br J Dermatol 152:690-696. (Pubitemid 40571301)
24. Liu B, et al. (1998) Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci USA 95:10626-10631. (Pubitemid 28413118)
25. Starr R, et al. (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387:917-921. (Pubitemid 27289594)
26. Ito S, et al. (1999) Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 93:1456-1463. (Pubitemid 29102470)
27. Larner AC, Petricoin EF, Nakagawa Y, Finbloom DS (1993) IL-4 attenuates the transcriptional activation of both IFN-alpha and IFN-gamma-induced cellular gene expression in monocytes and monocytic cell lines. J Immunol 150:1944-1950. (Pubitemid 23129672)
28. Park IK, Shultz LD, Letterio JJ, Gorham JD (2005) TGF-beta1 inhibits T-bet induction by IFN-gamma in murine CD4+ T cells through the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-1. J Immunol 175:5666-5674. (Pubitemid 41508048)
29. Viguier M, et al. (2004) Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444-1453. (Pubitemid 38924326)
30. Serafini P, Borrello I, Bronte V (2006) Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16:53-65. (Pubitemid 43139709)
31. Gabrilovich D, et al. (1998) Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92:4150-4166. (Pubitemid 28544331)
32. Moschos SJ, et al. (2006) Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24:3164-3171. (Pubitemid 46638955)
33. Kirkwood JM, et al. (2002) Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer 95:1101-1112. (Pubitemid 34925363)
34. Feng X, et al. (2002) Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol 129:205-215. (Pubitemid 34874925)
35. He XS, et al. (2006) Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 44:352-359. (Pubitemid 44214874)
36. Rousson V (2002) On distribution-free tests for the multivariate two-sample location-scale model. J Multivariate Anal 80:42-57.